NASDAQ: VRDN
Viridian Therapeutics Inc Stock Ownership - Who owns Viridian Therapeutics?

Insider buying vs selling

Have Viridian Therapeutics Inc insiders been buying or selling?

Buy
Sell
NameRoleDateSharesPriceValue
Fairmount Funds Management LLCDirector2025-06-1012,500$12.31
$153.88kBuy
Fairmount Funds Management LLCDirector2025-06-091,600$7.80
$12.48kBuy
Thomas W. BeethamChief Operating Officer2024-09-275,000$23.41
$117.05kBuy
Stephen F. MahoneyPresident and CEO2024-09-2721,400$23.33
$499.26kBuy

1 of 1

VRDN insiders have bought more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership

Be the first to know when VRDN insiders and whales buy or sell their stock.

VRDN Shareholders

What type of owners hold Viridian Therapeutics Inc stock?

Institutional
Insider
Retail
NameHoldSharesValueType
Fmr LLC14.99%12,238,803$230.95MInstitution
Logos Global Master Fund LP7.35%6,000,000$113.22MInsider
Blackrock Inc6.76%5,521,035$104.18MInstitution
Deep Track Capital LP6.59%5,380,449$101.53MInstitution
Commodore Capital LP5.97%4,875,000$91.99MInstitution
Vanguard Group Inc5.52%4,508,508$85.08MInstitution
Kynam Capital Management LP5.42%4,427,927$83.55MInstitution
Fairmount Funds Management LLC4.88%3,986,306$75.22MInsider
Vr Adviser LLC4.75%3,882,709$73.27MInstitution
Fairmount Funds Management LLC4.24%3,459,913$65.29MInstitution

1 of 3

VRDN vs Biotech Stocks

TickerInst. %Insider %Net Insider (L12M)Net Insider (L3M)
VRDN75.52%24.48%Net Buying
VERA66.54%33.46%Net BuyingNet Buying
EWTX88.36%11.64%Net BuyingNet Selling
ARDX42.58%57.42%Net BuyingNet Buying
BHVN81.99%18.01%Net Buying

Viridian Therapeutics Stock Ownership FAQ

Who owns Viridian Therapeutics?

Viridian Therapeutics (NASDAQ: VRDN) is owned by 115.79% institutional shareholders, 37.53% Viridian Therapeutics insiders, and 0.00% retail investors. Logos Global Master Fund LP is the largest individual Viridian Therapeutics shareholder, owning 6.00M shares representing 7.35% of the company. Logos Global Master Fund LP's Viridian Therapeutics shares are currently valued at $113.22M.

If you're new to stock investing, here's how to buy Viridian Therapeutics stock.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.